The HLA-DRB family genes are notably lesser in number in NSTAS patients than in NSCLC patients, , suggesting an increase in tumor immune evasion, reduction of T-cell recognition and activation, and a further confirmation of decreased immunogenicity of cancer cells (Wang L. et al., 2022; Datar et al., 2021). The gene discussed is HLA-DRB1; the disease is neoplasm.